<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo> (SAH) model in rats was produced by the injection of homologous blood into the cisterna magna </plain></SENT>
<SENT sid="1" pm="."><plain>Effects of AJ-3941 ((+/-)-(E)-1-(3-fluoro-6,11 -dihydrodibenz[b,e]-oxepine-11-yl)-4-(3-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-2-propenyl)-p iperazine dimaleate, CAS 143110-70-7) on the development of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> and the change of regional cerebral blood flow (rCBF) following SAH was investigated in this model </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">Cerebral vasospasm</z:e> following SAH showed a biphasic pattern with an early phrase at 10 min and a late phrase on 1 day after blood injection </plain></SENT>
<SENT sid="3" pm="."><plain>The physiological parameters (blood pressure, heart rate and blood gas contents) remained stable within the physiological range throughout the course of the experiment </plain></SENT>
<SENT sid="4" pm="."><plain>AJ-3941 (0.01 mg/kg i.v. or 0.3 mg/kg p.o.) significantly prevented the development of late phase <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Cisternal injection of homologous blood significantly reduced rCBF immediately after the injection and the reduction lasted during the observation period (30 min) </plain></SENT>
<SENT sid="6" pm="."><plain>Reduction in rCBF after the injection of homologous blood was prevented by AJ-3941 (0.01 mg/kg i.v.) </plain></SENT>
<SENT sid="7" pm="."><plain>rCBF in AJ-3941-treated rats completely returned to the basal values after 30 min </plain></SENT>
<SENT sid="8" pm="."><plain>The present suggest that AJ-3941 may be useful in the prevention of late spasm and in the improvement of cerebral circulation impaired with SAH </plain></SENT>
</text></document>